Michael Jenkins currently serves as the SVP of Manufacturing for ARMR Sciences, Inc. Michael most recently served as the VP of Operations at iBio, Inc., as site head for the manufacture of large molecules. He led an 85-person site team during successful transition to full Phase 1-3 cGMP compliance. Prior to that, Dr. Jenkins was the SVP of Chemistry, Manufacturing and Controls (CMC) for Ridgeback Biotherapeutics, where he was responsible for a US government-funded monoclonal antibody therapeutic program for Ebola – a Material Threat Medical Countermeasure program approved in Dec 2020. As a Senior CMC consultant for BioProcess Technology Consultants (BPTC), Michael was responsible for contract negotiations and oversight of contract drug manufacturing organizations (CDMOs), the preparation of regulatory reports and submissions, and the design of an antibody-drug conjugate (ADC) Phase 1/2 manufacturing facility.